Aspire Biopharma Holdings, Inc. is calling a June 9, 2026 special meeting to seek stockholder approval for several warrant-related actions tied to a financial advisory agreement and the acquisition of Direct Control Systems.
The key proposal asks stockholders to approve, for Nasdaq Rule 5635(d) purposes, the issuance of pre-funded warrants and the common shares issuable upon exercise, including any Warrant Shares above 19.99% of common stock outstanding on April 2026 at a nominal exercise price of $0.00001 per share. Additional proposals would authorize adjustments to the number of shares underlying the warrants under Section 3.2 of the Warrant Agreement, permit voluntary reductions of the warrant exercise price under Section 3.8, and allow adjournments of the meeting to gather more votes if needed. The Board recommends voting “FOR” all four proposals. Stockholders of record as of April 13, 2026, when 5,024,142 common shares were outstanding, are entitled to vote.
Aspire Biopharma Holdings, Inc. closed a $21.0 million private placement and strengthened its balance sheet while pursuing a major acquisition. The company completed the second and final tranche of its Series A Convertible Preferred Stock financing, issuing 12,500 shares for $10.0 million, bringing total proceeds to $21.0 million and lifting stockholders’ equity above the $2.5 million Nasdaq Capital Market minimum. Aspire plans to use the cash for working capital, to help fund the proposed acquisition of Dura Control Systems (DCS), and for general corporate purposes. It has a Letter of Intent to buy 100% of DCS, which generated more than $20 million in Adjusted EBITDA on over $200 million of 2025 revenue, for a $30 million all-cash purchase price. To finance this, Aspire obtained a commitment letter for a senior secured credit facility of up to $22.5 million on a five-year term at an interest rate 325 basis points above the one‑month term Secured Overnight Financing Rate.
Aspire Biopharma Holdings, Inc. completed a private placement Offering of 25,000 shares of Series A Convertible Preferred Stock for gross proceeds of about $21,000,000, split across two tranches. The first tranche closed on February 6, 2026 for 13,750 shares and $11,000,000, including conversion of $943,801 of existing debt.
On April 15, 2026, the company closed the second tranche for 12,500 shares and approximately $10,000,000 in gross proceeds. Net proceeds are intended to fund the cash component of a proposed Dura Driver Control Systems acquisition and for general corporate purposes. The company also filed a Certificate of Amendment designating 30,000 shares of Series A Convertible Preferred Stock with a par value of $0.0001 and stated value of $1,000 per share.
Aspire Biopharma Holdings, Inc. completed a private Offering of Series A Convertible Preferred Stock and amended the terms of this preferred class. The company has now issued 13,750 preferred shares for gross proceeds of $11,000,000 at the initial closing and an additional 12,500 preferred shares for $10,000,000 at a second closing on April 15, 2026.
Each preferred share has a stated value of $1,000 and is convertible into common stock at a price equal to 80% of the lowest closing price over five recent trading days, but not below a floor equal to 20% of the Nasdaq “Minimum Price,” subject to adjustments. Conversions are capped so that an investor generally cannot beneficially own more than 4.99% of outstanding common stock, adjustable up to 9.99% with notice.
The Certificate of Designation was amended on April 13, 2026 to designate 30,000 Series A preferred shares. Aspire states that, as a result of the Offering, it believes stockholders’ equity now exceeds $2.5 million, meeting the minimum requirement for continued listing on The Nasdaq Capital Market, and it awaits Nasdaq’s formal confirmation.
Aspire Biopharma Holdings, Inc. held a Special Meeting of Stockholders on April 10, 2026, where a quorum of stockholders voted on several proposals. The 8-K reports that all matters presented at the meeting were approved based on the tabulated voting results.
The disclosed proposals received votes in favor ranging from 1,466,141 to 2,096,356, with varying levels of opposition, abstentions, and broker non-votes. The filing confirms the outcomes of these stockholder votes and is signed by Chief Executive Officer Kraig Higginson.
Aspire Biopharma Holdings, Inc. has signed a non-binding Letter of Intent to acquire Dura Driver Control Systems (DCS), a tier-one automotive and industrial systems supplier. Aspire expects to buy 100% of DCS for $30 million in cash, subject to due diligence and a definitive agreement.
For the fiscal year ended December 31, 2025 (unaudited), DCS generated more than $200 million in revenue, over $17 million in net income and over $22 million in Adjusted EBITDA. DCS supplies mechatronic actuators, human‑machine interfaces, industrial cables and control systems, backed by more than 310 patents and 11 manufacturing facilities worldwide.
The contemplated acquisition would diversify Aspire beyond biopharmaceutical drug delivery technology into a higher‑revenue industrial and automotive platform. The company cautions there is no assurance a definitive agreement will be finalized or that the transaction will close, and any deal would be subject to customary conditions and audited financials.
Aspire Biopharma Holdings, Inc. entered into a non-binding letter of intent to acquire 100% of the Driver Controls Systems business unit of Firefish Topco, LLC for an enterprise value of $30.0 million on a cash-free, debt-free basis, payable in cash at closing.
The LOI includes reciprocal break-up fees of $3.5 million under specified failure-to-close or bad-faith scenarios, as well as a 30-day no-shop period for the sellers, subject to possible extension. Most LOI terms are non-binding, and completion depends on negotiating and signing a definitive purchase agreement and satisfying closing conditions. Following a completed acquisition, the company plans to engage Lakewood & Company, LLC to provide management services for DCS, subject to a separate definitive management agreement.
Aspire Biopharma Holdings, Inc. is registering up to 159,090,906 shares of common stock for resale by existing investors, issuable upon conversion of its Series A Convertible Preferred Stock. These selling shareholders, not the company, will receive any proceeds from share sales.
The Preferred Stock supports up to $20 million of financing, with a first tranche of $11 million already funded on February 6, 2026 and a potential second tranche of up to $10 million contingent on conditions including effectiveness of this registration. The preferred converts at a variable price with a $0.264 per-share floor and a 4.99%–9.99% beneficial ownership cap, limiting how much common stock any holder can own after conversion.
Aspire is an early-stage biopharmaceutical and supplements company focused on patent-pending sublingual delivery technology. Its lead high-dose sublingual aspirin product has completed a positive pharmacokinetic clinical study showing faster blood availability and stronger platelet inhibition than standard oral aspirin, with a 505(b)(2) NDA submission targeted for 2026. The company is also advancing sublingual melatonin, vitamin, caffeine and other formulations, including its “Buzz Bomb” caffeine supplement line.
Aspire Biopharma Holdings, Inc. files an amended annual report to add its independent auditor’s report and related certifications, with no other changes to the original Form 10-K for the year ended December 31, 2025.
The company describes itself as an early-stage biopharmaceutical developer of patent-pending sublingual drug delivery technologies, led by a high‑dose sublingual aspirin program progressing toward a planned 505(b)(2) NDA submission. As of March 27, 2026, Aspire had 5,024,124 shares of common stock outstanding, and the aggregate market value of voting stock held by non‑affiliates was about $17.4 million as of December 31, 2025.
Aspire Biopharma Holdings, Inc. filed its annual report outlining its transformation from SPAC PowerUp into a commercial‑stage biopharma platform focused on novel sublingual drug delivery, led by a high‑dose aspirin program for suspected acute myocardial infarction and multiple supplement and therapeutic candidates.
The company reports a reverse recapitalization valuing Aspire Biopharma, Inc. at $350 million, multiple convertible financings and a $100 million equity line of credit to fund development. As of March 27, 2026, there were 5,024,124 shares of common stock outstanding. Aspire highlights positive pharmacokinetic data from a 2025 sublingual aspirin trial supporting a planned 505(b)(2) NDA in 2026 and early commercial rollout of its Buzz Bomb caffeine supplement.